艾力斯(688578.SH)：甲磺酸伏美替尼片 EGFR PACC突变NSCLC一线治疗适应症纳入拟突破性治疗品种公示

Core Viewpoint - The company艾力斯 (688578.SH) has announced that its core product,甲磺酸伏美替尼片 (brand name "艾弗沙®"), has been included in the list of proposed breakthrough therapies by the National Medical Products Administration (NMPA) of China, targeting first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR PACC mutations [1] Group 1 - The proposed indication for伏美替尼 is for adult patients with locally advanced or metastatic NSCLC with EGFR PACC mutations [1] - The public announcement period for this proposed breakthrough therapy is from December 25, 2025, to January 4, 2026 [1]